Article info
PDFCommentary
Carvedilol: the β-blocker of choice for portal hypertension?
- Correspondence to Professor Jaime Bosch, Liver Unit, Hospital Clínic-IDIBAPS, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hepatic Hemodynamic Laboratory, C. Villarroel 170, Barcelona 08036, Spain; jbosch{at}clinic.ub.es
Citation
Carvedilol: the β-blocker of choice for portal hypertension?
Publication history
- First published January 26, 2013.
Online issue publication
April 18, 2016
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions